Differentiation therapy: a promising strategy for cancer treatment
Open Access
- 6 January 2016
- journal article
- perspective
- Published by Springer Nature in Chinese Journal of Cancer
- Vol. 35 (1) , 1-3
Abstract
Poor differentiation is an important hallmark of cancer cells, and differentiation therapy holds great promise for cancer treatment. The restoration of IkB kinase α (IKKα) leads to the differentiation of nasopharyngeal carcinoma cells with reduced tumorigenicity. The findings by Yan et al. validate the polycomb protein enhancer of zeste homologue 2 (EZH2) as a target for intervention.Keywords
This publication has 15 references indexed in Scilit:
- Ovarian cancer standard of care: are there real alternatives?Chinese Journal of Cancer, 2015
- IKKα restoration via EZH2 suppression induces nasopharyngeal carcinoma differentiationNature Communications, 2014
- Radiotherapy of high-grade gliomas: current standards and new concepts, innovations in imaging and radiotherapy, and new therapeutic approachesChinese Journal of Cancer, 2014
- The Pivotal Role of IKKα in the Development of Spontaneous Lung Squamous Cell CarcinomasCancer Cell, 2013
- IKKα Is Required to Maintain Skin Homeostasis and Prevent Skin CancerCancer Cell, 2008
- Focus on nasopharyngeal carcinomaCancer Cell, 2004
- IκB kinase-α acts in the epidermis to control skeletal and craniofacial morphogenesisNature, 2004
- IKKα controls formation of the epidermis independently of NF-κBNature, 2001
- Limb and Skin Abnormalities in Mice Lacking IKKαScience, 1999
- Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)New England Journal of Medicine, 1991